| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | C1sb |
| Uniprot No | Q8CFG8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 16-688aa |
| 氨基酸序列 | EPTMHGEILSPNYPQAYPNDVVKSWDIEVPEGFGIHLYFTHVDIEPSESCAYDSVQIISGGIEEGRLCGQRTSKSPNSPIIEEFQFPYNKLQVVFTSDFSIEEQFTGFAAYYTAIDVNECTDFTDVPCSHFCNNFIGGYFCSCPPEYFLHDDMRNCGVNCSGDVFTALIGEISSPNYPNPYPENSRCEYQIQLQEGFQVVVTMQREDFDVEPADSEGNCPDSLTFAAKNQQFGPYCGDGFPGPLTIRTQSNTLGIVFQTDLMGQKKGWKLRYHGDPISCPKESTANSNWEPDKAKYVFKDVVKITCVDGFEVVEGHVSSTSYYSTCQSDGQWSNSGLKCQPVYCGIPDPIANGKVEEPENSVFGTVIHYTCEEPYYYMEHEEGGEYRCAANGRWVNDQLGIELPRCIPVCGVPTEPFQVQQKIFGGQPAKIENFPWQVFFNHPTAGGALINEYWVLTAAHVVEKNSDPSMYAGITALRLADLENAQRLYTKRVIIHPGWKEDDDLNPRTNFDNDIALVQLKDPVKMGPKFSPICLPGTSSEYNLSPGDMGLISGWGRTEKRLHVINLRGAKVPVTSLETCKQVKEENPTARPEDYVITDNMICAGEKGVDSCKGDSGGAFAFQVPNVKAPKFYVAGLVSWGKKCGAYGVYTKVKNYVDWILKTMQENSGPRKD |
| 预测分子量 | 80.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C1sb重组蛋白的模拟参考文献示例(仅供参考，实际文献需通过学术数据库检索)：
---
1. **文献名称**: *Heterologous expression and functional characterization of C1sb protein in E. coli*
**作者**: Zhang Y, Liu X, Wang L
**摘要**: 研究报道了C1sb重组蛋白在大肠杆菌中的异源表达及纯化，通过优化表达条件提高蛋白可溶性，并验证其与DNA结合的功能特性，为后续结构研究奠定基础。
2. **文献名称**: *Structural insights into C1sb protein by X-ray crystallography*
**作者**: Li H, Chen J, Smith A
**摘要**: 利用X射线晶体学解析了C1sb重组蛋白的三维结构，揭示了其保守的β-桶状折叠模式及潜在的RNA/DNA结合位点，提示其在冷休克应激反应中的作用机制。
3. **文献名称**: *C1sb as a molecular chaperone: Implications in biotechnology*
**作者**: Wang Q, Patel R, Kumar S
**摘要**: 探讨了C1sb重组蛋白在低温环境下的分子伴侣功能，证明其可抑制蛋白质聚集并提高宿主细胞耐寒性，为工业酶低温催化提供潜在应用。
4. **文献名称**: *Functional analysis of C1sb mutations in bacterial stress adaptation*
**作者**: Tanaka K, Müller P, Lee C
**摘要**: 通过定点突变研究C1sb重组蛋白的关键结构域，发现特定氨基酸残基对细菌低温胁迫下的生存能力及基因表达调控至关重要。
---
**提示**：若需真实文献，建议在PubMed、Google Scholar等平台检索关键词“C1sb recombinant protein”或结合具体研究背景扩展搜索。
C1s recombinant protein is a key serine protease in the complement system, a critical component of innate immunity. It is part of the C1 complex (C1q-C1r-C1s), which initiates the classical pathway of complement activation. C1s, synthesized as a zymogen, is activated through proteolytic cleavage by C1r within the calcium-dependent C1 complex. Once activated, C1s cleaves complement components C4 and C2 to generate the C3 convertase (C4b2a), driving downstream immune responses such as opsonization, inflammation, and pathogen clearance. Dysregulation of C1s is linked to autoimmune disorders, including systemic lupus erythematosus, and complement-mediated diseases.
Recombinant C1s is produced using expression systems like mammalian cells (e.g., HEK293 or CHO) to ensure proper post-translational modifications and enzymatic activity. Its production enables detailed study of complement activation mechanisms, inhibitor screening, and structural analyses. Researchers use recombinant C1s to investigate its role in autoimmune pathologies or to develop therapeutic inhibitors, such as monoclonal antibodies or small molecules, targeting its proteolytic activity. Additionally, it serves as a tool in diagnostic assays to assess complement function or detect autoantibodies in patient samples.
The recombinant form offers advantages over plasma-derived proteins, including batch consistency, reduced contamination risks, and scalability. Mutagenesis studies using recombinant C1s have clarified residues critical for substrate recognition and interaction with regulators like C1-inhibitor. Its structural characterization (e.g., via crystallography) has revealed insights into substrate-binding domains and activation mechanisms. As complement-targeted therapies gain traction, recombinant C1s remains pivotal for both basic research and biopharmaceutical development, bridging insights into immune regulation and therapeutic innovation.
×
